Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab combined with concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
ChiCTR2100053476Phase 4Not yet recruiting
- Sponsor
- Cangzhou Central Hospital
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nimotuzumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Cangzhou Central Hospital. Primary endpoint: Median progression-free survival. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100053476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053476.